Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Endocrinology and Metabolism|April 14, 2015
High Diagnostic Accuracy Based on CLDN10, HMGA2, and LAMB3 Transcripts in Papillary Thyroid CarcinomaMateus Camargo Barros-Filho, Fabio Albuquerque Marchi, Clóvis Antônio Pinto, et al.
Advances in Experimental Medicine and Biology|February 10, 2020
Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour MicroenvironmentFlorian Guisier, Mateus Camargo Barros-Filho, Leigha D Rock, et al.
Frontiers in Oncology|December 13, 2019
Expanding the Transcriptome of Head and Neck Squamous Cell Carcinoma Through Novel MicroRNA DiscoveryLeigha D Rock, Brenda C Minatel, Erin A Marshall, et al.
Oral Oncology|May 22, 2019
Integrated miRNA and mRNA expression analysis uncovers drug targets in laryngeal squamous cell carcinoma patientsRainer Marco Lopez Lapa, Mateus Camargo Barros-Filho, Fabio Albuquerque Marchi, et al.
Brazilian Journal of Otorhinolaryngology|September 25, 2020
Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinomaLuis Rene Quiroa Barreno, Julia Bette Homem de Mello, Mateus Camargo Barros-Filho, et al.
Clinical Epigenetics|May 5, 2017
Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomasCaroline Moraes Beltrami, Mariana Bisarro Dos Reis, Mateus Camargo Barros-Filho, et al.
The Journal of Clinical Endocrinology and Metabolism|September 23, 2017
Prognostic Classifier Based on Genome-Wide DNA Methylation Profiling in Well-Differentiated Thyroid TumorsMariana Bisarro Dos Reis, Mateus Camargo Barros-Filho, Fábio Albuquerque Marchi, et al.
International Journal of Molecular Sciences|March 20, 2019
<i>PFKFB2</i> Promoter Hypomethylation as Recurrence Predictive Marker in Well-Differentiated Thyroid CarcinomasMateus Camargo Barros-Filho, Larissa Barreto Menezes de Lima, Mariana Bisarro Dos Reis, et al.
Oncology Letters|November 23, 2017
Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseasesDaniel Hardy Melo, Rui Celso Martins Mamede, Luciano Neder, et al.
Cancer Medicine|May 31, 2018
Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinomaMariana Rezende Alves, Natalia Cruz E Melo, Mateus Camargo Barros-Filho, et al.
Pageof 2